...
首页> 外文期刊>Die Pharmazie >Formulation and evaluation of antihyperglycemic leaf extracts of Zizyphus spina-christi (L.) Willd.
【24h】

Formulation and evaluation of antihyperglycemic leaf extracts of Zizyphus spina-christi (L.) Willd.

机译:Zizyphus spina-christi(L.)Willd抗降血糖叶提取物的配方和评价。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

This study deals with the formulation of antihyperglycemic leaf extracts of Zizyphus spina-christi (L.) Willd. A bioactivity guided fractionation of different leaf extracts [defatted ethanol 70% (a), butanol (b), ethanol 70% (c), ethyl acetate (d) and petroleum ether (e) extracts] revealed that extract (c) possessed the highest antihyperglycemic activity followed by (b) and (a). HPLC was adopted for standardization of the extract (c) based on evaluation of the major saponin christinin-A which was used as marker. The detection limit was 9.45 mg/ml for Christinin-A. Extracts (a), (b) and (c) were separately formulated in soft (S) and hard (H) gelatin capsules. Two different formulations (F1 and F2) were tried using different excipients suitable for oral drug delivery. Formula 1, used for soft gelatin capsules [(F1) Sa, Sb, Sc] Formula 2, used for hard gelatin capsules [(F2) - Ha, Hb, Hc]. The recovery rates of the samples of saponin were in the range 99.43-101.86% at 200, 800 microg/ml and 1200 microg/ml. Saponin release rates from different formulae were carried out using dissolution tester USP XXIV. The highest release was obtained from formulation Sc. The release of the extracts followed diffusion mechanism. The selected formula Sc exhibited highest anti-diabetic activity (P < 0.01) on acute and long-term administration and highest saponin release. This formula (Sc) contained poly-oxyethylene (20) cetyl ether (BC-20TX), PEG 400, PEG 6000, purified water, meglyol 810, ascorbic acid and 200 mg of extract (c).
机译:这项研究的目的是研究Zizyphus spina-christi(L.)Willd的抗高血糖叶提取物的配方。不同叶提取物的生物活性分级分离[脱脂的乙醇70%(a),丁醇(b),乙醇70%(c),乙酸乙酯(d)和石油醚(e)提取物]显示,提取物(c)具有最高的降血糖活性,其次是(b)和(a)。基于对主要皂苷克里斯汀-A(用作标记物)的评估,采用HPLC对提取物(c)进行标准化。 Christinin-A的检出限为9.45 mg / ml。提取物(a),(b)和(c)分别配制成软(S)和硬(H)明胶胶囊。使用适合口服药物递送的不同赋形剂尝试了两种不同的配方(F1和F2)。配方1,用于软明胶胶囊[(F1)Sa,Sb,Sc]配方2,用于软明胶胶囊[[F2)-Ha,Hb,Hc]。皂苷样品在200、800 microg / ml和1200 microg / ml的回收率在99.43-101.86%的范围内。使用溶出度测试仪USP XXIV进行不同配方中皂苷的释放速率。从制剂Sc获得最高的释放。提取物的释放遵循扩散机理。所选的配方Sc在急性和长期给药时显示出最高的抗糖尿病活性(P <0.01)和最高的皂苷释放。该式(Sc)包含聚氧乙烯(20)十六烷基醚(BC-20TX),PEG 400,PEG 6000,纯净水,乙二醇(Meglyol)810,抗坏血酸和200mg提取物(c)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号